dc.contributor.author | Loeffen, Jan L. C. | |
dc.contributor.author | Pillon, Marta | |
dc.contributor.author | Anderzhanova, Liliya | |
dc.contributor.author | Kabíčková, Edita | |
dc.contributor.author | Chiang, Alan K. S. | |
dc.contributor.author | Mellgren, Karin | |
dc.contributor.author | Lazic, Jelena | |
dc.contributor.author | Jazbec, Janez | |
dc.contributor.author | Meijerink, Jules P. P. | |
dc.contributor.author | Beishuizen, Auke | |
dc.contributor.author | Kebudi, Rejin | |
dc.contributor.author | Kroeze, Emma | |
dc.contributor.author | Arias Padilla, Laura | |
dc.contributor.author | Bakker, Max | |
dc.contributor.author | Boer, Judith M. | |
dc.contributor.author | Hagleitner, Melanie M. | |
dc.contributor.author | Burkhardt, Birgit | |
dc.contributor.author | Mori, Takeshi | |
dc.contributor.author | Attarbaschi, Andishe | |
dc.contributor.author | Verdú-Amorós, Jaime | |
dc.date.accessioned | 2023-02-21T08:51:24Z | |
dc.date.available | 2023-02-21T08:51:24Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Kroeze E., Arias Padilla L., Bakker M., Boer J. M., Hagleitner M. M., Burkhardt B., Mori T., Attarbaschi A., Verdú-Amorós J., Pillon M., et al., "Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement", Cancers, cilt.14, sa.16, 2022 | |
dc.identifier.issn | 2072-6694 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_234db765-35b9-49f2-988d-23757f8ece22 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/187025 | |
dc.identifier.uri | https://doi.org/10.3390/cancers14163895 | |
dc.identifier.uri | https://avesis.istanbul.edu.tr/api/publication/234db765-35b9-49f2-988d-23757f8ece22/file | |
dc.description.abstract | © 2022 by the authors.B-cell lymphoblastic lymphoma (BCP-LBL) and B-cell acute lymphoblastic leukemia (BCP-ALL) are the malignant counterparts of immature B-cells. BCP-ALL is the most common hematological malignancy in childhood, while BCP-LBL accounts for only 1% of all hematological malignancies in children. Therefore, BCP-ALL has been well studied and treatment protocols have changed over the last decades, whereas treatment for BCP-LBL has stayed roughly the same. Clinical characteristics of 364 pediatric patients with precursor B-cell malignancies were studied, consisting of BCP-LBL (n = 210) and BCP-ALL (n = 154) patients. Our results indicate that based on the clinical presentation of disease, B-cell malignancies probably represent a spectrum ranging from complete isolated medullary disease to apparent complete extramedullary disease. Hepatosplenomegaly and peripheral blood involvement are the most important discriminators, as both seen in 80% and 95% of the BCP-ALL patients and in 2% of the BCP-LBL patients, respectively. In addition, we show that the overall survival rates in this cohort differ significantly between BCP-LBL and BCP-ALL patients aged 1–18 years (p = 0.0080), and that the outcome for infants (0–1 years) with BCP-LBL is significantly decreased compared to BCP-LBL patients of all other pediatric ages (p < 0.0001). | |
dc.language.iso | eng | |
dc.subject | ONKOLOJİ | |
dc.subject | Tıp | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Sitogenetik | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Temel Bilimler | |
dc.subject | Kanser Araştırmaları | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | Klinik Tıp | |
dc.subject | Moleküler Biyoloji ve Genetik | |
dc.subject | BİYOKİMYA VE MOLEKÜLER BİYOLOJİ | |
dc.title | Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement | |
dc.type | Makale | |
dc.relation.journal | Cancers | |
dc.contributor.department | İstanbul Üniversitesi , Onkoloji Enstitüsü , Klinik Onkoloji Ana Bilim Dalı | |
dc.identifier.volume | 14 | |
dc.identifier.issue | 16 | |
dc.contributor.firstauthorID | 4113532 | |